K. Hirth
Chairman presso IO BIOTECH, INC.
Patrimonio netto: 928 491 $ in data 31/03/2024
Provenienza dei contatti di primo grado di K. Hirth
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 31 | |
| Public Company | Biotechnology | 22 | |
| Public Company | Pharmaceuticals: Major | 18 | |
12
| Private Company | Miscellaneous Commercial Services | 12 |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA.
12
| Subsidiary | Miscellaneous Commercial Services | 12 |
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA.
10
| Holding Company | Biotechnology | 10 |
Enterome SA
 Enterome SA Pharmaceuticals: MajorHealth Technology Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France.
10
| Holding Company | Pharmaceuticals: Major | 10 |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark.
9
| Subsidiary | Biotechnology | 9 |
Iconic Therapeutics, Inc.
 Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA.
8
| Subsidiary | Biotechnology | 8 |
Afferent Pharmaceuticals, Inc.
 Afferent Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Afferent Pharmaceuticals, Inc. develops selective drugs for the treatment of debilitating neurogenic disorders. It offers programs for respiratory, cardiovascular, chronic pain, biology, and clinical trials. The firm offers drugs for osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitis or bladder pain syndrome. The company was founded by Anthony P. Ford in December 2009 and is headquartered in San Mateo, CA.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
TRex Bio Ltd.
 TRex Bio Ltd. BiotechnologyHealth Technology TRex Bio Ltd. is a British company that provides biotechnology research and development services. The private company is based in London, UK. The company was founded in 2018 by Houman Ashrafian.
3
| Private Company | Biotechnology | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a K. Hirth tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| ABBOTT LABORATORIES | Medical Specialties | General Counsel Corporate Officer/Principal Corporate Officer/Principal | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Treasurer Corporate Officer/Principal Corporate Officer/Principal | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Investor Relations Contact Corporate Officer/Principal | |
| NPS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal General Counsel | |
| CYMABAY THERAPEUTICS, INC. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal General Counsel | |
FoldRx Pharmaceuticals LLC
 FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| CODEXIS, INC. | Chemicals: Specialty | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| FIVE PRIME THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO Chief Executive Officer Chief Tech/Sci/R&D Officer | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Chairman Corporate Officer/Principal Director/Board Member | |
| SUTRO BIOPHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member | |
| KURA ONCOLOGY, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal Private Equity Investor Private Equity Investor Private Equity Investor | |
| Dartmouth College | College/University | Undergraduate Degree Masters Business Admin Undergraduate Degree | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Miscellaneous | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| Yale University | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| Tufts University | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
| Santa Clara University | College/University | Masters Business Admin Undergraduate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
| University of California San Diego | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree Undergraduate Degree | |
| The University of California, San Francisco | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Graduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Graduate Degree Corporate Officer/Principal Graduate Degree | |
Juvaris BioTherapeutics, Inc.
 Juvaris BioTherapeutics, Inc. BiotechnologyHealth Technology Juvaris BioTherapeutics, Inc. develops novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The company was founded by Martin D. Cleary, Jeff Fairman and Steven W. Dow in February 2003 and is headquartered in Burlingame, CA. | Biotechnology | Director/Board Member Chief Executive Officer Founder | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
Polaris SA /FR/
 Polaris SA /FR/ Pharmaceuticals: MajorHealth Technology Polaris SA engages in the biotechnology industry and specializes in the field of healthy omega 3 lipids. The company was founded by St?phane Lozachmeur and Gildas Breton on July 1, 1994 and is headquartered in Quimper, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Harvard Medical School | College/University | Graduate Degree Corporate Officer/Principal | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Investment Managers | Private Equity Investor Corporate Officer/Principal Private Equity Investor | |
| DIMENSION THERAPEUTICS INC | Biotechnology | Director/Board Member Director of Finance/CFO | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree | |
| Harvard Business School | College/University | Graduate Degree Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| MAAT PHARMA | Pharmaceuticals: Major | Director/Board Member Founder | |
Orbus Therapeutics, Inc.
 Orbus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orbus Therapeutics, Inc. operates as a biopharmaceutical company focused on the development and commercialization of therapies that treat rare diseases. Its product eflornithine is a novel cytostatic agent, which the firm is developing to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The company was founded by Robert M. Myers and Jason D. Levin in 1998 and is headquartered in Palo Alto, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
CuraSen Therapeutics, Inc.
 CuraSen Therapeutics, Inc. BiotechnologyHealth Technology CuraSen Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapies to treat neurodegenerative diseases, including parkinson, alzheimer, and less common neurodegenerative disorders. The company was founded by Mehrdad Shamloo, Robert Booth, Anthony Ford, and Kathleen Sereda in 2018 and is headquartered in San Mateo, CA. | Biotechnology | Director/Board Member Founder | |
| MODERNA, INC. | Biotechnology | Human Resources Officer Director/Board Member | |
| ENTRADA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| PASSAGE BIO, INC. | Biotechnology | Director/Board Member Director/Board Member Comptroller/Controller/Auditor | |
Neuron23, Inc.
 Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| VERA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chairman | |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 44 |
| Danimarca | 6 |
| Francia | 3 |
Settori
| Health Technology | 32 |
| Consumer Services | 13 |
| Finance | 4 |
| Commercial Services | 3 |
| Process Industries | 2 |
Posizioni
| Director/Board Member | 618 |
| Corporate Officer/Principal | 263 |
| Independent Dir/Board Member | 161 |
| Chief Executive Officer | 84 |
| Chairman | 81 |
Contatti più connessi
| Insiders | |
|---|---|
| Michael Ross | 44 |
| Heath Lukatch | 43 |
| Patrick Heron | 42 |
| Patrick Enright | 41 |
| Claus Asbjørn Andersson | 41 |
| Jack Nielsen | 38 |
| Todd Foley | 38 |
| Kurt von Emster | 34 |
| Georges Gemayel | 33 |
| James Manuso | 29 |
| Stephan Christgau | 29 |
| Charles Casamento | 27 |
| Jim Scopa | 26 |
| Carole Nüchterlein | 26 |
| William Greene | 26 |
- Borsa valori
- Insiders
- K. Hirth
- Connessioni Società
